Sunday Cecilia James, Kooffreh Mary E, Umoyen John A, Ubi Godwin M*, Agbor Reagan B, Ekerette Emmanuel E and Ekpenyong Blessing B

Department of Genetics and Biotechnology, Faculty of Biological Sciences, University of Calabar, Calabar, Nigeria

*Corresponding Author: Ubi Godwin M, Department of Genetics and Biotechnology, Faculty of Biological Sciences, University of Calabar, Calabar, Nigeria.

Received: January 05, 2023; Published: February 09, 2023

Abstract

This research investigated the oncogenic properties and protein structure variations of mutations in the mouse double minutes 2 (MDM2) gene implicated in liver cancer patients in the University of Calabar Teaching Hospital, Calabar. Forty five liver cancer patients and fifty controls were recruited for the study. Blood samples were collected for molecular analysis. DNA was isolated from the blood samples of all the subjects and sequenced for the presence of MDM2 gene mutation. The chromatogram was decoded into nucleotide sequences using Chromas Pro and later translated to protein sequences. Bioinformatics tools were used to unveil the oncogenic characteristics, functional partners of MDM2 gene/protein interactions and the MDM2 protein structure variations. The result revealed significant differences in oncogenic characteristics as molecular weights, theoretical isoelectric points, total number of atoms, size of gene, G-C content, extinction coefficient, estimated half- life, instability index, aliphatic index, total positively and negatively charged amino acids and hydropathicity of the MDM2 gene for both patient and control group isolates. The results of MDM2 gene oncology /protein interactions revealed strong relationship and interactions with functional partners of major genes and proteins such as MDM4, TP53, TP57, RLP11, EP300, UPST and CDKN2A proteins. Results of secondary protein structures for the MDM2 gene isolates showed variations in the percentage distribution of alpha helices, beta sheets, extended strands and random coil. The tertiary protein structure further revealed the double mouse shape of the gene which accounts for the name mouse double minutes 2 gene. Knowledge of the oncogenic characteristics of the mutated and non-mutated MDM2 gene and the variations that exist in the protein structure characteristics can play a major significant role in the design and development of therapy for liver cancer disease and further help to unmasked the genetic factors and interactions that trigger the loss of functions and deviant expressivity of the mutated MDM2 gene among patients. Hence, the findings of this study serve as baseline information for further studies on the genetic etiology of the disease.

Keywords: MDM2 Gene Oncology; Alpha Helices; Tertiary Structure; Molecular Characteristics; Biological Process

References

1. Yoon YJ., et al. “MDM2 and p53polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection”. Carcinogenesis 29.6 (2008): 1192-1196.
2. Chen J., et al. “Mapping of the p53 and mdm-2 interaction domains”. Molecular Cell Biology 13 (1993): 4107-4114.
3. Kooffreh M E., et al. “Modifying and adapting a plant-based extraction protocol for human genomic DNA extraction: a cost effective approach”. Global Journal of Pure and Applied Sciences 23 (2017): 1-
4. Dagogo-Jack I and Shaw A T. “Tumor heterogeneity and resistance to cancer therapies”. Nature Review on Clinical Oncology 15 (2018): 81-94.
5. Abd Elhameed A H., et al. “Study of P53 gene mutations as a new early diagnostic marker of hepatocellular carcinoma in Egyptian patients”. Madridge Journal of Oncogenesis 2.1 (2018): 21-29.
6. Abudu EK and Akinbami OS. “Histologic profile of primary gastrointestinal malignancies in Uyo City”. Rare Tumours1 (2016): 6183.
7. Chia TS., et al. “Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection”. Hepatoma Research 5 (2019): 9-23.
8. Arzumanyan A., et al. “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma”. Nature Review in Cancer 13 (2013): 123-135.
9. Bond GL., et al. “A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans”. Cell 119 (2004): 591-602.
10. Ezzikouri S., et al. “MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population”. Cancer Detection and Prevention Journal 32 (2009): 380-385.
11. Bosetti C., et al. “Hepatocellular carcinoma epidemiology”. Best Practice Research in Clinical Gastroenterology 28 (2014): 753-770.
12. Buseri FI., et al. “Surveying infections among pregnant women in the Niger Delta, Nigeria”. Journal of Global Infectious Disease 2 (2010): 203-211.
13. Candotti D., et al. “Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa”. Journal of Virology 77 (2003): 7914-7923.
14. Cevik D., et al. “Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations”. World Journal of Gastroenterology1 (2015): 311-317.
15. Chen YL., et al. “TERT promoter mutation in hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection”. International Journal of Surgery 12 (2014): 659-665.
16. Di Vuolo V., et al. “TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients”. Infectious Agents and Cancer 6 (2011): 13-18.
17. Duan L., et al. “Identification of serum β‑cateninas a biomarker in patients with HBV‑related liver diseases”. Journal of Translational Medicine 16 (2018): 265-271.
18. Duan X and Li J. “Association between MDM2 SNP309, p53 Arg72Pro and hepatocellular carcinoma risk a moose-compliant meta-analysis”. Medicine 96 (2017): 36-42.
19. Ebughe GA., et al. “The pattern of cancer cases in the rest of Cross River State not covered by Calabar cancer regiter between 2004- 2013. Journal of Tropical Disease and Health1 (2019): 1-12.
20. Edamoto Y., et al. “Alterations of RB1, p53 and Wnt pathwaysin hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis”. International Journal of Cancer3 (2003): 334-341.
21. Fusco M., et al. “Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer”. European Journal of Cancer 6 (2008): 847-853.
22. Gouas D A., et al. “TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in the Gambia”. Carcinogenesis6 (2012): 1219-1224.
23. He F., et al. “The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma”. Pharmacogenomics and Personalized Medicine 14 (2021): 723-736.
24. Ibrahim I A and Pondei K. “Hepatitis B and C infection: should gynaecological patients be routinely screnned?” International Journal of Medicine and Biomedical Research 1 (2014): 2-4.
25. Inyang-Etoh P C., et al. “Occurrence of Hepatitis B and C Viral infections among pregnant women in Calabar, Cross River State, Nigeria”. Journal of Advances in Microbiology 1 (2016): 1-9.
26. Inyang-Etoh PC., et al. “Occurrence of hepatitis ‘B’ and ‘C’ amongst patients on antiretroviral drug therapy (ART) in a treatment centre in Calabar, Nigeria”. International Journal of Medicine and Medical Sciences6 (2014): 158-160.
27. Jedy-Agbaa E., et al. “Cancer incidence in Nigeria: A report from population-based cancer registries”. Cancer Epidemiology5 (2012): 271-278.
28. Jeannel D., et al. “Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa”. Journal of Medical Virology 55 (1998): 92-97.
29. Gomez K., et al. “Somatic evolutionary timings of driver mutations”. Biomedical Central in Cancer 18 (2018): 85-92.
30. Jiao J., et al. “Prevalence of Aflatoxin associated TP53R249S mutation in hepatocellular carcinoma in Hispanics in South Texas”. Cancer Preventive Research 11 (2018): 103-112.
31. Kancherla V., et al. “Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma”. Frontiers in Genetics 9 (2018): 2-16.
32. Kooffreh-Ada M., et al. “Frequency of Hepatitis B and C Co-Infection in Chronic Liver Disease Patients in Calabar, Cross River State, Nigeria”. Nigerian Journal of Physiological Science 31 (2016): 043-047.
33. Laraba A., et al. “Hepatitis C virus infection in Nigerians with chronic liver disease”. The International Journal of Gastroenterology 9 (2010): 17-24.
34. Leu JD., et al. “Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population”. World Journal of Gastroenterology44 (2009): 5592-5597.
35. Lovet J M., et al. “Hepatocellular carcinoma”. Nature Reviews (Disease Primers) 6 (2021): 1-28.
36. Ma R., et al. “MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? (review)”. Oncology Letters 21 (2021): 324-330.
37. Mak D., et al. “Analysis of risk factors associated with hepatocellular carcinoma in black South Africans: 2000-2012”. Plos One5 (2018): 1-14.
38. Min Q., et al. “Beta-catenin and Yes-associated protein 1 cooperate in hepatoblastoma pathogenesis”. The American Journal of Pathology, 5 (2019): 1091-1104.
39. Mohd HK., et al. “Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence”. Hepatology 57 (2013): 1333-1342.
40. Morounke SG., et al. “Epidemiology and incidence of common cancers in Nigeria”. Journal of Cancer Biology and Research3 (2017): 1105-1117.
41. Ndom P. “Cancer prevention in Africa: liver cancer”. Electronic Cancer 13 (2019): 950-958.
42. Neamatallah MA., et al. “TP53 polymorphism as a risk factor for hepatocellular carcinoma in hepatitis C virus-infected Egyptian patients”. Egyptian Journal of Basic and Applied Sciences 1 (2014): 9-15.
43. Njouom R., et al. “The hepatitis C virus epidemic in Cameroon: genetic evidence for rapidtransmission between 1920 and 1960”. Infection and Genetic Evolution 7 (2007): 361-367.
44. Nwafor C C and Nwafor NN. “The pattern and distribution of cancers in Akwa Ibom State, Nigeria”. Nigerian Journal of Clinical Practices 21 (2018): 603-608.
45. Nwokediuko SC., et al. “Pattern of liver disease admissions in a Nigerian tertiary hospital”. Nigerian Journal of Clinical Practice3 (2013): 399-342.
46. Obiora U J. “Cancer among women of reproductive age in Nigeria”. Asian Journal of Medical Sciences3 (20210): 42-46.
47. Ochei K C., et al. “Merit Research Prevalence of hepatitis B and C from samples received from the various wards in Niger Delta University Teaching Hospital (NDUTH), Okolobiri forhaematological analyses”. Journal of Medicine and Medical Sciences 4 (2016): 204-209.
48. Okeke E., et al. “Epidemiology of liver cancer in Africa: current and future trends”. Seminar in Liver Disease 39 (2019): 55-66.
49. Okpokam DC., et al. “Hepatitis D virus in chronic liver disease patients with hepatitis B surface antigen in University of Calabar Teaching Hospital, Calabar, Nigeria”. British Journal of Medicine and Medical Research 3 (2015): 312-318.

Citation

Citation: Sunday Cecilia James., et al. “Oncogenic Characteristics, Functional Partners and Protein Structure Variations in Isolated MDM2 Gene among Liver Cancer Patients in UCTH, Calabar, Nigeria”.Acta Scientific Medical Sciences 7.3 (2023): 65-75.

Copyright

Copyright: © 2022 Sunday Cecilia James., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.